Fresh Tracks Therapeutics 미래 성장

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Fresh Tracks Therapeutics 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

OTCPK:FRTX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2023	8	-6	-4	-4	N/A
9/30/2023	10	-9	-6	-6	N/A
6/30/2023	3	-17	-13	-13	N/A
3/31/2023	7	-16	-14	-14	N/A
12/31/2022	7	-21	-19	-19	N/A
9/30/2022	5	-23	-22	-22	N/A
6/30/2022	5	-30	-28	-28	N/A
3/31/2022	0	-40	-40	-40	N/A
12/31/2021	0	-39	-36	-36	N/A
9/30/2021	0	-41	-36	-36	N/A
6/30/2021	0	-32	-29	-29	N/A
3/31/2021	1	-26	-19	-19	N/A
12/31/2020	2	-21	-20	-20	N/A
9/30/2020	2	-24	-29	-29	N/A
6/30/2020	4	-25	-38	-38	N/A
3/31/2020	5	-24	-37	-37	N/A
12/31/2019	8	-14	-36	-36	N/A
9/30/2019	10	-7	-26	-26	N/A
6/30/2019	12	-6	-19	-19	N/A
3/31/2019	9	-7	-4	-4	N/A
12/31/2018	11	-15	4	4	N/A
12/31/2017	8	-23	-9	-9	N/A

애널리스트 미래 성장 예측

수입 대 저축률: FRTX 의 예상 수익 증가율이 절약률( 2.6% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: FRTX 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: FRTX 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: FRTX 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: FRTX 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: FRTX 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Fresh Tracks Therapeutics 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Price target increased to US$72.50

Consensus forecasts updated

Consensus estimates of losses per share improve by 25%

Consensus revenue estimates increase by 26%

Consensus revenue estimates increase by 159%

Consensus revenue estimates fall by 47%

Recent updates

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics, Inc. Announces Executive Changes

New minor risk - Revenue size

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.43 loss in 2Q 2022)

Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately

First quarter 2023 earnings released: US$1.14 loss per share (vs US$3.55 loss in 1Q 2022)

Full year 2022 earnings released: US$7.52 loss per share (vs US$22.12 loss in FY 2021)

Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023

Fresh Tracks Therapeutics, Inc. Announces Publication of Preclinical Data for FRTX-02

Price target increased to US$72.50

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Fresh Tracks Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus estimates of losses per share improve by 25%

Fresh Tracks Therapeutics Appoints Deepak Chadha to the Additional Position of Chief Operating Officer

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of Dyrk1a Inhibitor FRTX-02

Brickell Biotech changes name to Fresh Tracks Therapeutics

Insufficient new directors

Brickell Biotech Receives Notice from the Nasdaq Stock Market in Relation to Non-Compliance with the Independent Director and Audit Committee Requirements

Consensus revenue estimates increase by 26%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Brickell Biotech, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Brickell Biotech, Inc. Announces Resignation of Dennison T. Veru from the Board of Directors

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

Brickell Biotech regains Nasdaq compliance for minimum bid price requirement

Brickell Biotech Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Brickell Biotech, Inc. Announces Executive Changes

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

Consensus revenue estimates increase by 159%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Brickell Biotech, Inc. to Report Q1, 2022 Results on May 12, 2022

Consensus revenue estimates fall by 47%

Price target decreased to US$2.67

Full year 2021 earnings: EPS and revenues miss analyst expectations

Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.43 loss in 2Q 2020)

Co-Founder & Chairman of the Board recently bought US$134k worth of stock

Brickell Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Brickell Biotech, Inc. Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech Announces Initiation of A Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by Its Development Partner, Kaken Pharmaceutical in Japan

Brickell Biotech Receives A Notice from Listing Qualifications Department of Nasdaq Stock Market

Brickell Biotech, Inc. Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.45 loss in 1Q 2020)

Brickell Biotech Advances To Phase III As It Eyes Commercialization

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech completes patient enrollment in late-stage sweat disorder study

CEO & Director recently bought US$118k worth of stock

Brickell Biotech, Inc., Annual General Meeting, Apr 19, 2021

Full year 2020 earnings released: US$0.85 loss per share (vs US$4.50 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Brickell Biotech, Inc. to Report Q4, 2020 Results on Mar 09, 2021

New 90-day high: US$1.38

New 90-day high: US$1.29

Brickell Biotech, Inc. Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (Ecclock®)

Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.

New 90-day high: US$1.22

Brickell Biotech, Inc. Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study

Brickell Biotech (BBI) Investor Presentation - Slideshow

Brickell Biotech, Inc. Announces Management Changes

Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26